Skip to main content

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • FDA ordered strict warning for anemia drug Feraheme

    The US Food and Drug Administration (FDA) is ordering stricter warnings and contraindications for the anemia drug “Feraheme”. It could cause potentially life-threatening allergic reactions. The drug — approved for use only in adults with chronic kidney disease who have iron-deficiency anemia — has been contraindicated also in patients with known hypersensitivity to ferumoxytol or any of its components or a history of allergic reaction to any intravenous iron product. Health care professionals should strictly follow the recommendations mentioned in the drug label. Patients should immediately call doctor if there is breathing problems, low blood pressure, lightheadedness, dizziness, swelling, a rash, or itching during or after Feraheme administration.

  • FDA approves breath test for treatment of gastroparesis

    The U.S. Food and Drug Administration approved the Gastric Emptying Breath Test (GEBT), a new non-invasive test for the treatment of delayed gastric emptying, known as gastroparesis. Gastroparesis is a condition in which your stomach cannot empty itself of food in a normal fashion. It is caused by damage to the vagus nerve, which regulates the digestive system. A damaged vagus nerve prevents the muscles in the stomach and intestine from functioning, preventing food from moving through the digestive system properly. If this left untreated, gastroparesis can lead to problems such as severe dehydration due to persistent vomiting, difficulty managing blood sugar levels in people with diabetes, and malnutrition due to poor absorption of nutrients or a low caloric intake.

  • Biocon Strengthens its Presence in Mexico, Receives Approval for Insulin Glargine through its Partner PiSA Farmaceutica

    Biocon Ltd, Asia's premier biopharmaceuticals company, announced that its Insulin Glargine has been approved by COFEPRIS, the Mexican health authority, through its partner PiSA Farmaceutica (PiSA).

  • Glenmark receives US FDA approval for norethindrone acetate and ethinyl estradiol tablets USP

    Glenmark Generics Inc. USA, a subsidiary of Glenmark Generics, has received the final approval from the United States Food and Drug Administration (USFDA) for sale of drugs meant to prevent post-menopause osteoporosis.USFDA granted Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 0.5 mg/2.5 mcg and 1 mg/5 mcg.

  • Live monitoring of fetal heart rate, First time in india

    The cumbersome days of stressful, manual, wired monitoring of the unborn child in pregnant mothers will soon end - thanks to a new system unveiled at a hospital here. The Lokmanya Tilak Municipal General Hospital, known as the Sion Hospital, has introduced system in order to monitor the fetal heart rate and condition of the baby in the uterus of a pregnant lady for the first time in India.

  • Chemical to Trap Malaria Mosquitoes Identified

    In a world first, researchers have found that a naturally occurring chemical attracts pregnant malaria transmitting mosquitoes - a discovery which could boost malaria control efforts. The chemical, cedrol, found in mosquito breeding sites near Africa's Lake Victoria, could be used in traps that would 'attract and kill' the female mosquito, preventing reproduction before she lays hundreds of eggs.

  • Vitamin D may Help Treat Age related Diseases

    Vitamin D may play a vital role in the prevention and treatment of chronic diseases associated with ageing such as diabetes and cancer, according to new research. Researchers reviewed evidence that suggests an association between vitamin D deficiency and chronic diseases associated with ageing such as cognitive decline, depression, osteoporosis, cardiovascular disease, high blood pressure, Type 2 diabetes and cancer.

  • In US, Up to 2020, RA treatment market value to reach $9.3 bn

    According to business intelligence provider GBI (GlobalBusinessIntelligence) Research In 2013,  The US treatment market for rheumatoid arthritis (RA) was $6.4 billion and which get rising to $9.3 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 5.5%. Resaon behind this sudden growth  is US’ increasing prevalent population, which is reported  to hit 1.68 million by 2020. Consequently, marketcurrently makes up the  largest treatmentarea of the eight major pharmaceutical markets (the US, UK, Canada, France, Germany, Spain, Italy and Japan).

Subscribe to Pharma News

Search this website